Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with Aavishkar Oral Strips.
The patent, titled “Nicotine Bilayer Oral Film and Process for Preparation Thereof,” has been granted by the Indian Patent Office under Patent Number IN 582202, based on Patent Application No. IN 202441055689 filed July 22, 2024 under the Patent Cooperation Treaty (PCT) framework.
The patent covers Rapid Dose Therapeutics’ bilayer oral thin film technology designed for controlled nicotine delivery, including proprietary formulation and manufacturing processes that support rapid absorption and discreet administration through dissolvable oral strips.
The grant represents a major step in the Company’s global intellectual property strategy, which began with its World Intellectual Property Organization (WIPO) PCT filing announced in May 2025. That filing extended potential patent protection to up to 158 jurisdictions worldwide, strengthening the Company’s global positioning within the rapidly expanding smoke-free nicotine products market.
Stocks to Watch today alongside Rapid Dose (CSE: DOSE) (OTCQB: RDTCF) are MDJM LTD (NASDAQ: UOKA), Signing Day Sports (NYSE: SGN), Tenaya Therapeutics Inc (NASDAQ: TNYA) and Mag Mile Capital (OTCQB: MMCP) active in early trading now!
The global modern oral nicotine market was valued at approximately $7.96 billion in 2024 and is projected to reach $38.89 billion by 2033, growing at a 19% compound annual growth rate (CAGR). Growth is being driven by increasing demand for smoke-free nicotine alternatives, rising awareness of the health risks of combustible cigarettes, and continued innovation in nicotine replacement therapy and oral nicotine delivery systems.
Rapid Dose Therapeutics’ QuickStrip™ oral thin film platform is designed to deliver active ingredients—including nicotine, pharmaceuticals, nutraceuticals, and vaccines—through fast-dissolving oral films that enable rapid onset and improved bioavailability.
India represents both a significant consumer market and a major global pharmaceutical manufacturing hub, making the patent strategically important as Rapid Dose continues executing its global expansion strategy.
The Company also noted that the milestone supports ongoing commercial discussions with a major global nicotine company, with whom Rapid Dose has been engaged for nearly three years.
Management believes that the combination of granted patents, global PCT coverage across 158 jurisdictions, and strategic partnerships strengthens Rapid Dose Therapeutics’ competitive position as it advances commercialization opportunities for its QuickStrip™ nicotine oral film technology.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
